Literature DB >> 6221695

Comparative in vitro study of teichomycin A2.

V Fainstein, B LeBlanc, G P Bodey.   

Abstract

Teichomycin A2 was evaluated in vitro against clinical isolates, and its activity was compared with that of other antibiotics. This compound was very active against all organisms tested; its activity was comparable to that of vancomycin, and it was superior to several other antibiotics when tested against gram-positive cocci. Because of its in vitro activity, it deserves clinical evaluation.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6221695      PMCID： PMC184679          DOI： 10.1128/AAC.23.3.497

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients.

Authors:  G P Bodey; R Feld; M A Burgess
Journal:  Am J Med Sci       Date:  1976 Mar-Apr       Impact factor: 2.378

2.  Bacteremia due to gram-positive cocci in patients with neoplastic disease.

Authors:  L J Kilton; B E Fossieck; M H Cohen; R H Parker
Journal:  Am J Med       Date:  1979-04       Impact factor: 4.965

3.  Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.

Authors:  M H Cynamon; P A Granato
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  Comparative in vitro study of SQ26,776.

Authors:  V Fainstein; S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

5.  Bacteremia due to Staphylococcus aureus in patients with cancer: report on 45 cases in adults and review of the literature.

Authors:  D N Carney; B E Fossieck; R H Parker; J D Minna
Journal:  Rev Infect Dis       Date:  1982 Jan-Feb

6.  Increasing incidence of Gram-positive sepsis in cancer patients.

Authors:  P A Pizzo; S Ladisch; R M Simon; F Gill; A S Levine
Journal:  Med Pediatr Oncol       Date:  1978

7.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties.

Authors:  F Parenti; G Beretta; M Berti; V Arioli
Journal:  J Antibiot (Tokyo)       Date:  1978-04       Impact factor: 2.649

8.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. II. Extraction and chemical characterization.

Authors:  M R Bardone; M Paternoster; C Coronelli
Journal:  J Antibiot (Tokyo)       Date:  1978-03       Impact factor: 2.649
  8 in total
  16 in total

1.  Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection.

Authors:  W E Peetermans; J J Hoogeterp; A M Hazekamp-van Dokkum; P van den Broek; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

2.  Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

Authors:  H F Chambers; S Kennedy
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 4.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 5.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

6.  Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

7.  Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci.

Authors:  C U Tuazon; H Miller
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  In vitro activity of teichomycin compared with those of other antibiotics.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

9.  Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.

Authors:  M R Bibler; P T Frame; D N Hagler; R B Bode; J L Staneck; V Thamlikitkul; J E Harris; A Haregewoin; W E Bullock
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

10.  [Perioperative cefamandole prevention in aortocoronary bypass operations: the course of serum levels in extracorporeal circulation].

Authors:  W Klepetko; A Georgopoulos; W Graninger; J Miholic; W Sandtner
Journal:  Langenbecks Arch Chir       Date:  1984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.